NuVasive First-to-Market With New Spine Innovations Featured at NASS 2016

Go back to NuVasive First-to-Market With New Spine Innovations Featured at NASS 2016

Jefferies Reiterates Buy on NuVasive (NUVA) Following 3Q Report

October 26, 2016 8:34 AM EDT

Jefferies reiterated a Buy rating and $72.00 price target on NuVasive (NASDAQ: NUVA) following the company's 3Q earnings report. For the year, the company is now guiding to $952mn in sales (down from $962mn). Components of this include the US capital stocking issue of... More